Sanofi
SNYHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeSanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. With a market capitalization of $99.68B, it sits in large-cap territory. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Market Cap
$99.68B
Beta
0.28
P/E (TTM)
21.89
P/E (Fwd)
7.96
EPS (TTM)
$1.90
EPS (Fwd)
$5.23
ROE
5.7%
ROA
5.1%
Cash
$6.35B
Total Debt
$23.58B
Free CF
$6.30B
52W Change
-19.1%
Annual Financials
Cash vs Debt
Where SNY stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SNY finished 8.61% below its 150-day moving average ($43.30) and 9.18% below its 200-day moving average ($43.57). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SNY overbought or oversold?
At the October 20, 2026 close, SNY's RSI(14) was 41.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, SNY has $6.35B in cash with $23.58B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $6.30B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 5.7% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been uneven over recent years, ranging from $40.56B to $46.72B.
With a beta below 0.7, Sanofi typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Sanofi's trajectory.